Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
2,130 enrolled
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Phase 2 Recruiting
63 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Phase NA Recruiting
420 enrolled
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
276 enrolled
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 Recruiting
40 enrolled
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
30 enrolled
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Phase 3 Recruiting
550 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Phase 3 Recruiting
387 enrolled
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3 Recruiting
555 enrolled
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Phase 2 Recruiting
116 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Phase 1 Recruiting
49 enrolled
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2 Recruiting
106 enrolled
Remission
Phase 2 Recruiting
30 enrolled
BIG
Phase 2 Recruiting
120 enrolled
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2 Recruiting
40 enrolled
NEO-CLAUD
Phase 1/2 Recruiting
57 enrolled
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3 Recruiting
269 enrolled
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/2 Recruiting
55 enrolled
OCTASUR
Phase 2/3 Recruiting
150 enrolled
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2 Recruiting
51 enrolled
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 Recruiting
110 enrolled
PREVENT
Phase 3 Recruiting
200 enrolled
Neo-ICEBOAT
Phase 2 Recruiting
53 enrolled
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Phase 2 Recruiting
40 enrolled
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Phase 3 Recruiting
286 enrolled
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Phase 3 Recruiting
486 enrolled
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 Recruiting
90 enrolled
EXPLORING
Phase 2 Recruiting
80 enrolled
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Phase 3 Recruiting
110 enrolled
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2 Recruiting
140 enrolled
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Phase NA Recruiting
95 enrolled
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Phase 2 Recruiting
38 enrolled
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Phase 3 Recruiting
976 enrolled
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Phase 3 Recruiting
433 enrolled
GASPACCO
Phase NA Recruiting
304 enrolled